Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Histamine-1 receptor antagonist adverse event reports that FDA received for the drugs of this class

Kind of class
Pharmacologic class (FDA Established Pharmacologic Class)
Drug pages
34

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

Histamine-1 receptor antagonist is a pharmacologic class: an FDA Established Pharmacologic Class. The class has 34 drug pages on this site.

From January 2004 to June 2026, FDA received 135,666 adverse event reports that name a drug of the class. In these reports the drug is a suspect or interacting product. A report that names two drugs of the class counts one time for each.

FDA received 10,050 reports in the 12 months to June 2026 and 12,083 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 10,050 (0.8%) name a drug of the class. Reports for male patients were 22% of the reports that name a drug of the class and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

Pharmacologic class

The Established Pharmacologic Class (EPC) of FDA is the class on the label of a drug. The site puts a drug in the class that its reports have most often.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs of the class

The rows are in order of name. A brand name and its generic name are separate rows, because reporters name them separately.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drug pages of the class Histamine-1 receptor antagonist, in order of name
DrugName typeReportsReports, 12 months to June 2026
Aleve PMDiphenhydramine hydrochloride and naproxen sodiumBrand name1,87713
Allegra AllergyFexofenadine hydrochlorideBrand name7,868304
Allegra-DFexofenadine hydrochloride and pseudoephedrine hydrochlorideBrand name1,41421
AzelastineGeneric name1,54840
Azelastine hydrochlorideGeneric name2,502151
BenadrylDiphenhydramine hydrochlorideBrand name9,612432
CetirizineGeneric name12,5221,548
Cetirizine hclGeneric name8659
Cetirizine hydrochlorideGeneric name19,0922,043
Cetirizine hydrochloride and pseudoephedrine hydrochlorideGeneric name68582
Cetirizine hydrochloride, pseudoephedrine hydrochlorideGeneric name4,914909
Childrens ZyrtecCetirizine hydrochlorideBrand name81670
Childrens Zyrtec AllergyCetirizine hydrochlorideBrand name51410
Chlorpheniramine maleateGeneric name94281
Coricidin HBP Cough and ColdChlorpheniramine maleate, dextromethorphan hydrochlorideBrand name7171
DesloratadineGeneric name2,699190
DimenhydrinateGeneric name1,087121
DiphenhydramineGeneric name15,3391,157
Diphenhydramine hclGeneric name2,7410
Diphenhydramine hydrochlorideGeneric name5,556538
FexofenadineGeneric name3,142335
Fexofenadine hclGeneric name1,1190
Fexofenadine hydrochlorideGeneric name1,499208
GravolDimenhydrinateBrand name968127
Hydrocodone polistirex and chlorpheniramine polistirexGeneric name9508
LastacaftAlcaftadineBrand name73714
Levocetirizine dihydrochlorideGeneric name72892
OlopatadineGeneric name1,00410
Pataday Once Daily ReliefOlopatadine hydrochlorideBrand name1,008205
Tylenol PmAcetaminophen and diphenhydramine hydrochlorideBrand name62440
XyzalLevocetirizine dihydrochlorideBrand name3,824181
Xyzal Allergy 24HRLevocetirizine dihydrochlorideBrand name5,302147
ZyrtecCetirizine hydrochlorideBrand name20,342929
Zyrtec-DCetirizine hydrochloride and pseudoephedrine hydrochlorideBrand name1,10934

Reaction lookup

These are the reaction terms that the reports of the class record. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 2,348 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 134,545 of the 135,666 reports (99.2%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

The table shows the first 50 of 2,348 terms.

Reaction terms in the reports that name a histamine-1 receptor antagonist drug, most reports first
Reaction term (MedDRA) and plain meaningReportsShare of the 135,666 reports
Drug ineffectivethe medicine did not work as expected31,21223%
Fatiguetiredness18,70113.8%
Off label useused for a purpose or in a way not on the label16,86912.4%
Painpain, site not specified16,73912.3%
Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease14,48810.7%
Rashskin rash13,73310.1%
Abdominal discomfortstomach discomfort13,3689.9%
Alopeciahair loss12,9319.5%
Systemic lupus erythematosuslupus, an autoimmune disease12,8899.5%
Hypersensitivityan allergic-type reaction12,6739.3%
Pemphigus12,5619.3%
Infusion related reactiona reaction during or soon after an infusion12,4979.2%
Glossodynia11,9198.8%
Headachehead pain11,6318.6%
Swelling11,3078.3%
Product use issuea problem in how the product was used11,2228.3%
Hand deformity10,8588%
Joint swellinga swollen joint10,6447.8%
Hepatic enzyme increasedraised liver enzymes10,5667.8%
Pruritusitching10,5577.8%
Wound10,5227.8%
Contraindicated product administered10,3607.6%
Arthropathy10,3347.6%
Drug intolerancethe medicine was not tolerated10,2857.6%
Maternal exposure during pregnancythe mother took the medicine during pregnancy10,1857.5%
Nauseafeeling sick9,9977.4%
Pericarditisinflammation of the sac around the heart9,9967.4%
Treatment failurethe treatment did not work9,9777.4%
Arthralgiajoint pain9,9437.3%
Synovitis9,6877.1%
Pyrexiafever9,0836.7%
Condition aggravatedthe condition being treated got worse9,0626.7%
Dyspnoeashortness of breath9,0606.7%
Product use in unapproved indicationused for a purpose not on the label8,9946.6%
Discomfort8,8666.5%
Vomitingbeing sick8,5616.3%
Anti-cyclic citrullinated peptide antibody positive8,5326.3%
Dizzinesslight-headedness or unsteadiness8,4356.2%
Hypertensionhigh blood pressure8,3216.1%
Somnolencedrowsiness8,3046.1%
Urticariahives8,2286.1%
Duodenal ulcer perforation8,2076%
Malaisegeneral feeling of being unwell8,2066%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)8,1446%
Helicobacter infection8,0886%
Diarrhoealoose or frequent stools7,5465.6%
General physical health deteriorationgeneral decline in health7,2785.4%
Confusional stateconfusion7,1655.3%
Nasopharyngitisa cold7,0295.2%
Blistera blister6,9275.1%

Download all 2,348 terms of the class (CSV)

The counts add to more than 135,666 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Reports by month

Reports that name a histamine-1 receptor antagonist drug, by month, five years to June 2026
01,0002,00020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Outcomes, patients and reporters

Outcomes in the reports of the class Histamine-1 receptor antagonist
OutcomeReportsShareShare as a bar
Death25,77519%
Life-threatening14,07410.4%
Hospitalization (initial or prolonged)27,55920.3%
Disability or Permanent Damage14,25010.5%
Congenital Anomaly/Birth Defect5,4314%
Other Serious (Important Medical Events)59,09543.6%
Not serious57,32842.3%

An outcome in a report is not proof that a drug was the cause. The reporter gives the outcome, and FDA does not verify it. A report can have more than one outcome. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Age of the patient in the reports of the class Histamine-1 receptor antagonist
AgeReportsShareShare as a bar
Under 29310.7%
2 to 113,5242.6%
12 to 172,9552.2%
18 to 4428,33120.9%
45 to 6419,90814.7%
65 to 748,5976.3%
75 and over7,4395.5%
Age not given63,98147.2%
Type of reporter in the reports of the class Histamine-1 receptor antagonist
ReporterReportsShareShare as a bar
Physician18,83813.9%
Pharmacist5,3523.9%
Other health professional39,71229.3%
Lawyer1410.1%
Consumer or non-health professional68,96750.8%
Not given2,6562%

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Reported Reactions. Histamine-1 receptor antagonist: adverse event reports that FDA received. https://reportedreactions.com/class/histamine-1-receptor-antagonist/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The class of a drug is the Established Pharmacologic Class that openFDA attaches to its reports most often. When the reports have none, it is the class in the NDC Directory. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Which drugs are in the Histamine-1 receptor antagonist class on this site?

Aleve PM, Allegra Allergy, Allegra-D, Azelastine, Azelastine hydrochloride, Benadryl and 28 more, in order of name. The class of a drug comes from the pharmacologic class (EPC) on its FDA label.

Can the table of drugs rank the drugs?

No. FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Drugs also differ in the conditions that they treat and in their time on the market.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.